Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy.
Vaccine
; 28(40): 6621-6, 2010 Sep 14.
Article
em En
| MEDLINE
| ID: mdl-20656033
ABSTRACT
To assess B-cell function in patients under immunoglobulin (IgG)-replacement therapy, the non-licensed artificial bacteriophage (ΦX174)-neo-antigen may be used despite limited availability and experience. Active immunization against tick-borne encephalitis (TBE) is performed in few European countries. To test the feasibility of using licensed TBE vaccination as (neo-)antigen to determine residual or restored B-cell function in patients under regular IgG substitution, TBE-IgG levels were analyzed in 18 patients with ≥ 1-2 years of regular intravenous or subcutaneous IgG substitution and in pharmaceutical IgG-preparations (n=21 batches, 10 products). Six individuals were boosted against TBE. Although TBE-specific IgG was detectable in concentrates (281-57,100 VieU/0.5 µL), levels were only borderline in patient sera (n=31, 18 individuals; median 132 VieU; positive >155). Thus, TBE vaccination may be used to test B-cell function under IgG replacement therapy because IgG substitution appears insufficient to yield protective TBE-specific antibody levels in children.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
1_ASSA2030
/
4_TD
Problema de saúde:
1_medicamentos_vacinas_tecnologias
/
4_tick_borne_encephalitis
Assunto principal:
Imunoglobulina G
/
Vacinas Virais
/
Imunização Passiva
/
Encefalite Transmitida por Carrapatos
/
Síndromes de Imunodeficiência
/
Anticorpos Antivirais
Limite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Áustria